Form 4 for CLDI Calidi Biotherapeutics, Inc.

Accepted 2024-01-04 00:00:00 ET · period of report 2023-12-21 · accession 0001493152-24-001134 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-01-04	2023-12-21	CLDI	Schoeneck James A	Dir	A - Grant	$1.80	+10.6K	27.9K	+62%	+$19.1K
D	2024-01-04	2023-12-21	CLDI	Schoeneck James A	Dir	A - Grant	—	+70.2K	70.2K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-12-21	A	A	10,625	$1.80	27,872	D	—	—	(F2) Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date.
2	Derivative	Non-Qualified Stock Options (right to buy)	2023-12-21	A	A	70,249	—	70,249	D	$1.80 · — to 2033-12-21	70,249 Common stock	(F1) Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. The Options will vest in one year or next annual shareholder meeting, whichever first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.